Loading
Latest filing published 04 Dec 2025 for Sonnet BioTherapeutics Holdings, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Richard T. Kenney is a declared insider at 2 companies (senior executive); the most frequent names are Sonnet BioTherapeutics Holdings, Inc. and Immune Design Corp. Between 4 January 2016 and 2 December 2025, the trades on record add up to 15 filings.
No open-market sale appears; the market trades are 2 purchases worth €32k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 7 share grants and 2 option exercises.
The newest entry dates from 4 December 2025: a share grant, in Sonnet BioTherapeutics Holdings, Inc. The most recent open-market purchase was published on 9 June 2021, 1,963 days ago. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations